ArticleFrontiers in oncology2025
Focal boosted IMRT treatment of prostate cancer to 84 Gy in 28 fractions: preliminary clinical outcomes, toxicity, and dosimetry.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The FLAME trial reported that focal boosting of prostate tumors up to 95 Gy in 35 fractions improves biochemical control (disease-free survival). However, this treatment (regimen) is not commonly used in the United States. We investigated a focally boosted treatment of 84 Gy in 28 fractions (EQD2-108 Gy, BED 252 Gy). Methods: We retrospectively evaluated men with unfavorable intermediate-risk (uIR) and high-risk (HR) prostate cancer treated with focal boost intensity-modulated radiotherapy (IMRT) between 2019 and 2022. The dose levels were 84 Gy to the gross tumor volume (GTV), 70 Gy to the prostate and proximal seminal vesicles, and an optional 50.4 Gy to elective pelvic lymph nodes (all 28 fractions). The treatment planning goal was to cover 95% of the GTV at 84 Gy, and also meet the target and normal tissue dosimetry criteria of the hypofractionated treatment arm of NRG-GU005. Volume-modulated arc therapy was used for treatment delivery. Androgen deprivation therapy (ADT) was given at the discretion of the treating physician. Results: In total, 20 men were included in the analysis, 2 (10%) with uIR and 18 (90%) with HR. Six (30%) tumors were GG2, three (15%) GG3, seven (30%) GG4, and four (20%) GG5. There were 13 (65%) stage cT1, 4 (20%) cT2, and 3 (15%) cT3 tumors. One (5%) patient received short-term ADT, 18 (95%) long-term ADT, and 1 (5%) refused ADT. Moreover, 18 (90%) men received elective pelvic nodal radiation. The mean baseline Prostate specific antigen (PSA) was 25.1 ng/mL (range 4.2-73.4). The median baseline International Prostate Symptom Score (IPSS) was 11.1 (IQR 4.5-12). Four patients had severe baseline urinary symptoms (IPSS ≥20). The mean baseline prostate volume was 57.4 cc (range 26.8-198.3). The mean volume of the 84 Gy boost target was 7.1 cc (range 2.3-15.0) and the mean proportion of the prostate boosted was 14.8% (range 2%-47%). Patients met all per-protocol normal tissue criteria of NRG-GU005, except for bladder D0.03cc, with a reported mean of 79.2 (≤73.5 Gy). At a median follow-up of 42 months (range 18-63), no patients had developed recurrence, metastasis, or death from prostate cancer. One patient died at 18 months from unrelated metastatic colorectal cancer. Acute grade 1-2 genitourinary (GU) toxicity occurred in 13 (65%) patients, and acute grade 1-2 gastrointestinal (GI) toxicity occurred in 4 (20%) patients. No patients developed grade 3+ acute or late GU or GI toxicity. Conclusion: A novel 28-fraction focal boosted IMRT treatment is feasible and has an acceptable preliminary toxicity profile. Oncologic results are promising but require longer follow up and prospective study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.